Pharmaceutical profiling in drug discovery

Drug Discovery Today

Volumn 8, Issue 7, 2003, Pages 316-323

  Kerns, Edward H ^a   Di, Li ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

DECISION MAKING; DRUG INDUSTRY; DRUG SCREENING; DRUG STABILITY; ENZYME INHIBITION; EXPOSURE; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; METABOLISM; PERMEABILITY; PHYSICAL CHEMISTRY; PROTEIN BINDING; REVIEW; SOLUBILITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; DATABASES, FACTUAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037376928     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02649-7     Document Type: Review

References (61)

1. Prentis R.A., et al. Pharmaceutical innovation by the seven U.K.-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25:1988;387-396.
2. Kerns E.H., Di L. Multivariate pharmaceutical profiling for drug discovery. Curr. Top. Med. Chem. 2:2002;87-98.
3. van de Waterbeemd H., et al. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44:2001;1313-1333.
4. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv. Drug Deliv. Rev. 23:1997;3-25.
5. Smith D.A., van de Waterbeemd H. Pharmacokinetics and metabolism in early drug discovery. Curr. Opin. Chem. Biol. 3:1999;373-378.
6. Krämer S. Absorption prediction from physicochemical parameters. Pharm Sci. Technol. Today. 2:1999;373-380.
7. Venkatesh S., Lipper R.A. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89:2000;145-154.
8. Kerns E.H. High throughput physicochemical profiling for drug discovery. J. Pharm. Sci. 90:2001;1838-1858.
9. Obach R.S., et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283:1997;46-58.
10. Mandagere A.K., et al. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J. Med. Chem. 45:2002;304-311.
11. Caldwell G.W. Compound optimization in early- and late-phase drug development: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. Curr. Opin. Drug Discov. Dev. 3:2000;30-41.
12. Lipinski, C.A. (2001) Avoiding investment in doomed drugs, Curr. Drug Discov. April, 17-19.
13. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44:2000;235-249.
14. Eriksson, L. et al. (1999) Introduction to multi- and megavariate data analysis using projection methods (PCA & PLS). Umetrics AB Pub., Umea, Sweden.
15. Poulain R., et al. From hit to lead. Combining two complementary methods for focused library design. Application to μ opiate ligands. J. Med. Chem. 44:2001;3378-3390.
16. Veber D.F., et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45:2002;2615-2623.
17. Palm K., et al. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J. Med. Chem. 41:1998;5382-5392.
18. Clark D.E. Computational methods for the prediction of ADME and toxicity. Adv. Drug Deliv. Rev. 54:2002;253-254.
19. Kleintop, T. et al. (2001) LC/UV/MS method for integrity evaluation of pharmaceutical discovery compounds. Book of Absracts, ASMS Annual Conference, June 2000, Long Beach, CA, USA.
20. Bevan C., Lloyd R.S. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal. Chem. 72:2000;1781-1787.
21. Avdeef A. High throughput measurements of solubility profiles. Testa B., et al. Pharmacokinetic Optimization In Drug Research; Biological, Physicochemical, And Computational Strategies. 2001;305-326 Verlag Helvitica Chimica Acta.
22. Hansch, C. et al. Exploring QSAR, ACS Pub., Washington, DC1995.
23. Gulyaeva N., et al. Relative hydrophobicity and lipophilicity of beta-blockers and related compounds as measured by aqueous two-phase partitioning, octanol-buffer partitioning, and HPLC. Eur. J. Pharm. Sci. 17:2002;81-93.
24. H). Curr. Med. Chem. 8:2001;1137-1146.
25. Lombardo F., et al. ElogPoct: a tool for lipophilicity determination in drug discovery. J. Med. Chem. 43:2000;2922-2928.
26. Rourick R.A., et al. Predictive strategy for the rapid structure elucidation of drug degradants. J. Pharm. Biomed. Anal. 14:1996;1743-1752.
27. Kerns, E.H. et al. (2000) Stability profiling in drug discovery. Book of Abstracts, Symposium on Chemical and Pharmaceutical Structure Analysis. September 2000.
28. Barták P., et al. Determination of dissociation constants of cytokinins by capillary zone electrophoresis. J. Chromatogr. A. 878:2000;249-255.
29. Box K.J., et al. Rapid physicochemical profiling as an aid to drug candidate selection. Dixon G.K., et al. High Throughput Screening: The Next Generation. 2000;67-74 BIOS Scientific Publishers.
30. Korfmacher W.A., et al. Development of an automated mass spectrometry system for the quantitative analysis of liver microsomal incubation samples: a tool for rapid screening of new compounds for metabolic stability. Rapid Commun. Mass Spectrom. 13:1999;901-907.
31. Li, A.P. (2001) Higher-throughput screening assays with human hepatocytes for hepatotoxicity, metabolic stability, and drug-drug interaction potential. In: Drugs and the Pharmaceutical Sciences, 114 (Handbook of Drug Screening), pp. 383-402.
32. Wang G., et al. Semi-automated determination of plasma stability of drug discovery compounds using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 780:2002;451-457.
33. Janiszewski J.S., et al. A high-capacity LC/MS system for the bioanalysis of samples generated from plate-based metabolic screening. Anal. Chem. 73:2001;1495-1501.
34. Kerns E.H., et al. Buspirone metabolite structure profile using a standard liquid chromatographic-mass spectrometric protocol. J. Chromatogr. B Biomed. Sci. Appl. 698:1997;133-145.
35. Lopez L.L., et al. Identification of drug metabolites in biological matrices by intelligent automated liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 12:1998;1756-1760.
36. Shockcor J.P. Application of directly coupled LC-NMR-MS to the structural elucidation of metabolites of the HIV-1 reverse transcriptase inhibitor BW935U83. J. Chromatogr. B Biomed. Sci. Appl. 748:2000;269-279.
37. Artursson, P. (2002) Prediction of Drug Absorption: Caco-2 and Beyond. Book of Abstracts, PAMPA 2002 Conference, San Francisco, CA, 14-17 July 2002.
38. Ong S., et al. Immobilized-artificial membrane chromatography: measurements of membrane partition coefficient and predicting drug membrane permeability. J. Chromatogr. A. 728:1996;113-128.
39. Artursson P., et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46:2001;27-43.
40. Hidalgo I.J. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 1:2001;385-401.
41. Irvine J.D., et al. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88:1999;28-33.
42. Menard, C.A. et al. (2001) Comparison of Caco-2 permeability data in 24- and 96 well formats. Book of Abstracts. Lab Automation January, 2001.
43. Kansy M., et al. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41:1998;1007-1010.
44. Avdeef A., et al. Drug absorption in vitro model: filter-immobilized artificial membranes. 2. studies of the permeability properties of lactones in Piper methysticum Forst. Eur. J. Pharm. Sci. 14:2001;271-280.
45. Gumbleton M., Audus K.L. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J. Pharm. Sci. 90:2001;1681-1698.
46. Di, L. et al. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. (in press).
47. Van Asperen J., et al. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol. Res. 37:1998;429-435.
48. Polli J.W., et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299:2001;620-628.
49. Kim R.B. Transporters and drug disposition. Curr. Opin. Drug Discov. Dev. 3:2000;94-101.
50. Rodrigues A.D., Lin J.H. Screening of drug candidates for their drug-drug interaction potential. Curr. Opin. Chem. Biol. 5:2001;396-401.
51. Gao F., et al. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC50. J. Biomol. Screen. 7:2002;373-382.
52. Chu I., et al. Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes. Rapid Commun. Mass Spectrom. 14:2000;207-214.
53. Kerns E.H., et al. Cellular uptake profile of paclitaxel using liquid chromatography tandem mass spectrometry. Rapid Commun. Mass Spectrom. 12:1998;620-624.
54. Tiller P.R., et al. Immobilized human serum albumin: liquid chromatography/mass spectrometry as a method of determining drug-protein binding. Rapid Commun. Mass Spectrom. 9:1995;261-263.
55. Kariv I., et al. Development of a high throughput equilibrium dialysis method. J. Pharm. Sci. 90:2001;580-587.
56. Olah T.V., et al. The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionizaiton mass spectrometry as an in vivo drug screening procedure. Rapid Commun. Mass Spectrom. 11:1997;17-23.
57. Bajpai M., Adkison K.K. High-throughput screening for lead optimization: a rational approach. Curr. Opin. Drug Discov. Dev. 3:2000;63-71.
58. Korfmacher W.A., et al. Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. Rapid Commun. Mass Spectrom. 15:2001;335-340.
59. Gan L.S.L., Thakker D.R. Application of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv. Drug Deliv. Rev. 23:1997;77-98.
60. Tamvakopoulos C.S., et al. Determination of brain and plasma drug concentrations by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 14:2000;1729-1735.
61. Stoner C.L., et al. The implementation of an ADME enabling selection tool for drug discovery. AAPS Pharm. Sci. 4:2002;T3255.